country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-147792

Copy Link Print Information

WNY1613

WNY1613 is a potent and selective PI3Kδ inhibitor with piperazinone-containing purine scaffold. WNY1613 induces cancer cell apoptosis and inhibits the phosphorylation of PI3K downstream components in NHL cell lines. WNY1613 exhibits anti-NHL activity in vitro and in vivo.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2650546-39-5
Formel: C₂₉H₃₅N₉O₃
Molecular Weight:557.65

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

WNY1613 Chemical Structure

CAS. Nr.: 2650546-39-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle PI3K Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Granta-519	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human Granta-519 cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human Granta-519 cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]
JeKo-1	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human JeKo-1 cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human JeKo-1 cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]
NAMALVA	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human NAMALVA cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human NAMALVA cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]
OCI-Ly3	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human OCILY3 cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human OCILY3 cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]
SUD4	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human SU-DHL-4 cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human SU-DHL-4 cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]
SU-DHL-6	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human SU-DHL-6 cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human SU-DHL-6 cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]
WSUDLCL2	IC₅₀	0.038 μM Compound: 30; WNY1613	Antiproliferative activity against human WSUDLCL2 cells assessed as cell viability by non-radioactive cell proliferation MTT assay Antiproliferative activity against human WSUDLCL2 cells assessed as cell viability by non-radioactive cell proliferation MTT assay	[PMID: 36503229]

Chemical Information

CAS. Nr. 2650546-39-5
Molecular Weight 557.65
Formel C₂₉H₃₅N₉O₃
SMILES

O=C1N(CC2=NC3=C(N4CCOCC4)N=C(N5C6=CC=CC=C6N=C5CC)N=C3N2C)CCN(C(C7CCC7)=O)C1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zuo WQ, et al. Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma. Bioorg Chem. 2020;105:104344. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen